From MIDAS11 Dec 2023 13:11
The company's products, particularly focused on addressing MRSA, other post-operative infections, and chronic illness following antibiotic use, have the potential to generate annual sales exceeding £2 billion. It's noteworthy that the term used is "annual" sales, indicating a substantial revenue potential.
Destiny Pharma's drugs are strategically designed to reduce antibiotic use, accelerate recovery for the sick, and contribute to cutting healthcare costs. The emphasis on cost savings in healthcare aligns well with the priorities of the NHS.
As an illustrative example of what's possible, the text mentions GW Pharma, a cannabis group based in Cambridge, with sales of $400 million? a year which experienced a remarkable 25-fold increase in value in less than a decade. This surge occurred from its Nasdaq market floatation in 2013 at $8.90 per share to its acquisition for $220 per share just eight years later.